Medication info

Bonviva (Ibandronic Acid Sodium Monohydrate)

Prescription medicationSolutionInjection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Jeil Pharmaceutical co.,Ltd
Appearance
A colorless, transparent solution filled in a prefilled syringe with a single-use injection needle attached.
Packaging
1 prefilled syringe
Approval status
Active

MFDS item code 200611518 · Approved 2006.11.23 · Insurance code 645406251

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. There is insufficient clinical experience in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance less than 30ml/min, and administration of this medicine is not recommended for these patients. Elderly No dose adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children 18 years of age and younger.

Ingredients

Importer
Jeil Pharmaceutical co.,Ltd

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women. It helps to improve bone weakening caused by the decrease in female hormones after menopause, thereby reducing the risk of fractures.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. There is insufficient clinical experience in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance less than 30ml/min, and administration of this medicine is not recommended for these patients. Elderly No dose adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children 18 years of age and younger.

Precautions

This medication must be administered intravenously. Caution is required as injection into arteries or around veins can cause tissue damage. This medication should not be used in patients with allergy to the drug or its components, or in patients with untreated hypocalcemia. During treatment, side effects such as indigestion, abdominal pain, nausea, headache, rash, myalgia, and arthralgia may occur, but most are mild to moderate and do not warrant discontinuation of therapy. Occasionally, influenza-like symptoms such as fever, chills, fatigue, myalgia, and arthralgia may appear, but these symptoms generally resolve naturally within a short period. Prolonged use of this drug may rarely cause osteonecrosis of the jaw or bones surrounding the ear; therefore, especially for cancer patients or those undergoing dental treatment, it is advisable to have an oral examination before administration. If dental treatment is necessary, excessive dental procedures should be avoided while taking this medication, and decisions about whether to discontinue treatment should be made in consultation with a specialist. This medication may temporarily lower serum calcium levels, so it is important to treat hypocalcemia or bone metabolic disorders before administration and ensure sufficient intake of calcium and vitamin D. Patients with impaired kidney function or who are taking medications affecting the kidneys require regular monitoring and observation. During administration of this medication, sudden allergic reactions or anaphylaxis may occur; therefore, it should be given in an environment where emergency treatment is available. Women who are pregnant or breastfeeding are advised not to use this medication due to the lack of established safety. Overdose may cause issues with the kidneys and liver; if an overdose is suspected, immediate consultation with medical personnel and appropriate treatment is required. This medication should not be mixed with other intravenous medications or calcium-containing solutions, and it must be administered using a separate intravenous line. After administration, monitor closely for any adverse reactions, and report any abnormal symptoms to medical personnel immediately.

Side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illnesses, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, urticaria, uveitis, episcleritis, scleritis, anaphylactic reactions, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical electronic fractures, intertrochanteric femoral fractures, osteonecrosis of the jaw and outer ear canal, dizziness, optic atrophy, lower motor neuron lesions, tremors, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, acute renal failure, sensory loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air and moisture, and the storage temperature should be maintained at room temperature between 1 degree and 30 degrees Celsius. This helps to maintain the efficacy of the medication and prevent degradation.

Appearance and packaging

Appearance

A colorless, transparent solution filled in a prefilled syringe with a single-use injection needle attached.

Package unit

1 prefilled syringe

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.